# A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

> **NCT05650333** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 15 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Ritlecitinib 20 mg

## Key facts

- **NCT ID:** NCT05650333
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-02
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650333, "A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05650333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*